LexaGene’s Technology Identifies Genetic Mutations Directly from Cheek Swabs. Another huge market. $6Billion
LexaGene has demonstrated the ability for the same technology to be used for personal genotyping, which has a market value of greater than $6 B. The applications for genotyping (i.e. understanding genetic sequences in areas of scientific/clinical importance) are vast, including research focused on cancer and neurological diseases, as well as pharmacogenomic testing to determine a person’s genetic response to medication.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.